Clinical Trial Search

Phase 3 N=154 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Germline BRCA1/2 Mutations and · Metastatic Adenocarcinoma of the Pancreas

Primary: Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified…

AstraZeneca Results Jan 2020 25.2% serious AE View details

Phase 3 N=383 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis

Colitis, Ulcerative

Primary: Percentage of Participants Achieving Clinical Remission at Week 52 — 14.3; 46.2; 42.6 percentage of participants — p=<0.001

Takeda Results Jan 2020 10.4% serious AE View details

Phase 3 N=37 Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

Optic, Atrophy, Hereditary, Leber

Primary: Change From Baseline in ETDRS Visual Acuity (Quantitative Score) at Week 48 — -0.219; -0.211 LogMAR — p=0.8783

GenSight Biologics Results Jan 2020 8.1% serious AE View details

Phase 3 N=21 Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD

Cholestasis

Primary: Rate of Rise of Direct Bilirubin as a Function of Time — 1.033001353; 1.05457485; 1.025504411; 1.049318179 mg/dL/day

University of Michigan Results Jan 2020 42.9% serious AE View details

Phase 3 N=66 Stopping Cavities Study: Diammine Silver Fluoride

Dental Caries

Primary: Dental Caries Activity — .72; .05 Proportion of arrested caries lesions

Advantage Dental Services, LLC Results Jan 2020 0.0% serious AE View details

Phase 3 N=151 Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)

Opioid Use Disorders

Primary: Opioid Use — 6; 12; 7 Participants

University of California, Los Angeles Results Jan 2020 0.7% serious AE View details

Phase 3 N=129 Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia

Hypercholesterolemia · Dyslipidemia

Primary: Reduction of LDL Cholesterol Levels — -39.45; -29.13 percent change of LDL — p=0.0013

Ache Laboratorios Farmaceuticos S.A. Results Jan 2020 1.6% serious AE View details

Phase 3 N=10,061 Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Atherosclerosis

Primary: Analysis of Core Phase First CEC Confirmed Major Adverse Cardiovascular Events (MACE) and Its Components — 322; 320; 313; 535 Participants — p=0.0648

Novartis Pharmaceuticals Results Jan 2020 28.4% serious AE View details

Phase 3 N=615 Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) — 4.5; 10.6; 13.8…

Eli Lilly and Company Results Jan 2020 3.6% serious AE View details

Phase 3 N=44 Open Label Extension Study of AMG 531 in Japanese Subjects With ITP

Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Primary: Percentage of Participants With Adverse Events Including Clinically Significant Changes in Laboratory Values. — 100 percentage of participants

Kyowa Kirin Co., Ltd. Results Jan 2020 27.3% serious AE View details

Phase 3 N=197 A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients

Acute Pain

Primary: Total Rescue Opioid Consumption — 166.9; 179.9; 180.2 µg/kg — p=0.736

Mallinckrodt Results Jan 2020 1.5% serious AE View details

Phase 3 N=206 Linagliptin Add-on to Insulin Background Therapy

Diabetes Mellitus, Type 2

Primary: Percentage Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment — -0.20; -0.61 Percentage change — p=0.0016

Boehringer Ingelheim Results Jan 2020 13.1% serious AE View details

Phase 3 N=419 Lubiprostone for Children With Constipation

Constipation - Functional

Primary: Median Number of Observed Weekly Spontaneous Bowel Movements (SBM) Per Month — 2.66; 2.75; 2.70; 2.75 Weekly SBMs

Sucampo Pharma Americas, LLC Results Jan 2020 3.1% serious AE View details

Phase 3 N=971 Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

Insomnia Disorder

Primary: Change From Baseline in Subjective Sleep Onset Latency (sSOL) at Month 6 — 64.03; 62.19; 64.97; -16.57 minutes — p=<.0001

Eisai Inc. Results Jan 2020 3.2% serious AE View details

Phase 3 N=1,150 A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Metastatic Hormone Sensitive Prostate Cancer

Primary: Radiographic Progression-Free Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical Trials Working Group 2 (PCWG2)…

Astellas Pharma Global Development, Inc. Results Jan 2020 34.1% serious AE View details